Online monitoring of patient self-reported adverse events in early phase clinical trials : views from patients, clinicians, and trial staff by Kennedy, F. et al.
This is a repository copy of Online monitoring of patient self-reported adverse events in 
early phase clinical trials : views from patients, clinicians, and trial staff.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/168503/
Version: Published Version
Article:
Kennedy, F., Shearsmith, L., Ayres, M. et al. (5 more authors) (2020) Online monitoring of 
patient self-reported adverse events in early phase clinical trials : views from patients, 
clinicians, and trial staff. Clinical Trials. ISSN 1740-7745 
https://doi.org/10.1177/1740774520972125
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Article
CLINICAL
TRIALS
Clinical Trials
1–12
 The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1740774520972125
journals.sagepub.com/home/ctj
Online monitoring of patient self-
reported adverse events in early phase
clinical trials: Views from patients,
clinicians, and trial staff
Fiona Kennedy1 , Leanne Shearsmith1, Michael Ayres1, Oana C Lindner1,
Lewis Marston1, Alison Pass2, Sarah Danson2 and Galina Velikova1
Abstract
Background/aims: New classes of cancer drugs bring a range of unknown and undesirable adverse events. Adverse
event monitoring is essential in phase I trials to assess toxicity and safety. In phase II, the focus is also on efficacy but
robust data on adverse events continue to inform the safety and the adverse event profile. Standard, clinician-led moni-
toring has been shown to underestimate patients’ symptoms. Hence, patient-reported adverse event monitoring has
been argued to complement and improve the information on adverse events in early phase clinical trials. With advances
in information technology, real-time patient self-reported adverse events in trials are feasible. This study explored the
experiences and procedures for reporting adverse events in early phase trials among patients, clinical staff, and trial staff,
and their views on using an electronic patient-reported outcome adverse event system in this setting.
Methods: Qualitative interviews were conducted with patients, purposively sampled across ages, gender, and different
phases of trials, and with clinical and trial-related staff involved in early phase trials (e.g. consultants, research nurses,
hospital-based trial assistants/data managers, trial unit management staff). Interviews explored patient experiences and
views on current adverse event reporting processes and electronic patient-reported outcome adverse event reporting.
Framework analysis techniques were used to analyse the data.
Results: Interviewees were from two hospital trusts with early phase portfolios in England and a trial unit, and included
sixteen patients, five consultants, four research nurses, five hospital-based trial staff, and two trial unit staff. Interviews
identified three key themes (patient experiences, data flow, and views on electronic patient-reported outcome adverse
event reporting). Stakeholders emphasised the intensity of trials for patients and the importance of extensive informa-
tion provision within the uncertainty of early phase trial drugs. Regular face-to-face appointments for patients supple-
mented by telephone contact aimed to capture any adverse events. Delayed or under-reporting of mild- or low-severity
symptoms was evident among patients. Hospital-based staff highlighted the challenges of current data collection including
intense timescales, monitoring by trial sponsors, and high workload. Positive views on electronic patient-reported out-
come adverse events highlighted that this could provide a more comprehensive and accurate view on the side effects of
new drugs. Clinical staff emphasised patient safety and the need for clear responsibilities for monitoring. The need for
careful decision-making about data flow and symptom attribution was highlighted; with trial unit staff emphasising the
need for clinician review.
Conclusion: Technology advances mean it is timely to explore the benefits and challenges of electronic patient-
reported outcome adverse event reporting. This is a complex area warranting further consideration within the trial
community. We have developed an online patient self-reporting tool and a small pilot with early phase trial patients is
underway.
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Background
New treatments are continually being developed to
improve outcomes for patients living with advanced
cancer, which require extensive phase I–IV clinical trials
before they are used in routine clinical care. Novel
therapies with new modes of activity, such as targeted
agents and immunotherapy, are increasingly complex
and have unknown toxicity profiles that require moni-
toring during trials.1,2
In phase I trials (first-in-humans), the dose is gradu-
ally increased and safety, side effects, best dose, and tim-
ing are explored.3 In phase II, early evaluation of
efficacy is undertaken but safety and side effects are still
explored.3 Hereafter, we collectively refer to both these
phases as ‘early phase’ and accurate reporting of adverse
events is vital.4 Early phase trial patients can experience
significant toxicity which can reduce study duration.5
Adverse events are traditionally clinician-recorded using
the Common Terminology Criteria for Adverse Events
(CTCAE),6 relying on the clinician’s interpretation,
gauged through consultation with patients. Research
has consistently demonstrated that clinicians downgrade
symptom severity and under-report lower grade morbid-
ity with implications for patients’ survival, quality of
life, and trial outcomes.7–10
AWhite Paper published by Basch et al.11 highlighted
the importance of expanding the definition of drug toler-
ability to give more attention to patient experience – for
example, new treatments should be assessed carefully to
explore overall benefit through patient-derived sympto-
matic adverse events data, in addition to routinely evalu-
ated outcomes such as survival, clinician-derived
endpoints including dose modifications, CTCAE, and
healthcare utilisation. Therefore, the value of collecting
patient-reported outcomes directly from patients, unfil-
tered by clinicians, has been increasingly highlighted.2,11–13
From a US Food and Drug Administration perspec-
tive, Kim et al.14 highlight that patient-reported data
would not be reported directly to a drug regulator in
isolation, instead it is complementary to guide clinical
care15 and may trigger a clinical assessment. This may
lead to enhanced patient outcomes16–18 and more
informed drug prescribing and patient information.11,19
The National Cancer Institute has developed a patient-
reported outcome version of the CTCAE (PRO-
CTCAE), aiming to collect patient self-reported
adverse events in clinical trials.20 This approach is
clearly valuable, but there may be challenges in the
early phase trial setting, as participants can be unwell
and already significantly burdened by the trial pro-
cess.21–23 Qualitative research exploring early phase
trial patients’ experiences have focused on their
information needs and decision-making around enter-
ing trials.24,25 Therefore, their views on self-reporting
adverse events should be explored.
Recent technological advances mean real-time
patient-reported data collection is increasingly feasi-
ble.26–28 Electronic adverse events are convenient for
patients, increase data accuracy, reduce long-term
costs, and provide large datasets.15,16 Trial patients
often experience adverse events at home and in between
their regular hospital visits; therefore, real-time online
reporting may bridge the reporting gap and provide
information not captured by the current outpatient
methods. Furthermore, remote methods of monitoring
are even more relevant for immuno-compromised trial
patients who are especially vulnerable during the coro-
navirus disease 2019 (COVID-19) pandemic, facilitating
the triage of patients and reducing the need for face-to-
face clinical encounters where the risk–benefit ratio
deem it appropriate.29,30 Electronic methods also
enable the use of automated alerts for severe symptoms,
which could facilitate the management of patient-
reported adverse events in trials,31 but further work is
needed to explore a variety of stakeholders’ views and
whether this is acceptable in an early phase trial setting.
Recent early phase trials have explored patient-
reported adverse events, although mostly using paper-
based methods32,33 or waiting room tablet data collec-
tion,15,34,35 rather than remote, home-based online
methods. There is limited evidence of electronic patient-
reported outcome adverse events (ePRO-AEs) collec-
tion within early phase trials, although this is an
emerging area.36 This study aimed to explore the experi-
ences of reporting and monitoring adverse events
among relevant stakeholders within two large National
Health Service Trusts in England and their views of
using ePRO methods in this setting.
Methods
Semi-structured qualitative interviews were conducted
by one of four researchers (L.M., O.L., M.A., and
F.K.). A phenomenology qualitative approach was uti-
lised, as it is particularly useful in under-researched
areas, whereby each person’s unique view is considered
meaningful and valid.37 The researchers were not
known to patient participants and were independent
from the clinical and trial staff. Researchers were all
employed or seconded to the research group, thus
shared an interest in patient-reported outcomes.
Interview topic guide
The interview topic guides are depicted in Table 1.
Patient interviews explored their experience of trial
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information provision, symptom/side effect reporting,
and their views on using an online reporting system.
Staff interviews explored the adverse event reporting
process, and strengths, weaknesses, and challenges of
implementing ePRO-AEs in this setting.
Participants
Patient eligibility criteria included current or recent
phase I or II trials’ participation, ability to understand
and speak English, and having capacity to provide
informed consent. Patients were purposively sampled
aiming for one or two representatives across age (\60
years/.60 years), gender (female/male), and phase I or
phase II. The clinical team sought this information
from patient records, scoped eligibility and interest
from patients, and if interested passed details to the
researchers who made contact either face-to-face or via
telephone.
Staff members were identified through key individu-
als within the hospital/university early phase trial units,
then snowball sampling identified other relevant indi-
viduals (approached participants suggested other staff),
including consultants, principal investigators (PIs),
Table 1. Interview schedules for staff and patients.
Staff Patients
General views on reporting adverse events in early phase trials
 Tell me about the routine scheduled follow-up that
monitors early phase trial patients? (timing, frequency,
length of appointment, by whom, phase I versus phase II)
 Patients’ key point of contact when enrolled on an early
phase clinical trial?
 How are adverse events monitored in early phase clinical
trial patients? (phase I versus phase II)
 trial?
 How are adverse events recorded in early phase clinical
trials? (phase I versus phase II)
 Trial-related staff – Have you encountered concerning
patient-reported trial data in the past? If so, what actions
(if any) did you take in response to this? (phase I/phase II)
 What information are patients given about reporting
adverse events? How is it given (verbally/participant
information sheets)? (phase I versus phase II)
 trial?
 What do patients do [to report and monitor adverse
events?] out-of-hours?
 trial?
 Are there any key adverse events/symptoms that would
be applicable/important to monitor across early phase
trials?
Information provision
 Did you feel you had enough information about the
symptoms you may experience or which symptoms you
should contact the clinical team about?
 Were you told about any symptoms that could develop
related to the trial treatment?
 Who gave you this information? Written and/or verbal?
 Did you feel prepared about what to do, when and who to
contact while on trial?
 Who were you told to contact if you had a problem? Out-of-
hours?
Reporting side-effects/symptoms
 Have you had any problems with symptoms/side effects while
on the trial?
 Did you contact anyone about these?
 If not, why not? Any other action, i.e. self-medicate/wait for
routine appointment?
 If you did, who did you contact? Why did you contact them?
How did you get in contact? What happened following this
contact/reporting?
Views on electronic patient-reporting of adverse events in an early phase trials
 How often should patients be asked/reminded to
complete these? Should there be an option for completion
at any time if new adverse events are experienced?
 If the information goes directly to the clinical trial office/
database, if a patient reported a serious adverse event,
should the patient’s clinical team/trial-related team be
notified? (mild/moderate adverse events?)
 Who would be the best person to be notified?
 What level/frequency of information would you want to
be notified about (summary on day/week/etc.; only severe
adverse events or all adverse events)?
 trial?
 At what point would you want to be notified (in real-time,
prior to a review appointment with the patient)?
 trial?
 How do you think electronic adverse event patient-
reported data might impact on trial sponsors?
 What do you envisage to be the strengths and weaknesses
of a patient-reported adverse events being reported/
recorded in early phase trials?
 Any other challenges we should consider?
 Anything else?
 Do you have internet access, do you use a computer
regularly?
 How would you feel about self-reporting your symptoms
from home (in addition to review appointments you have
with the trial/clinical team)?
 How often/regularly would it be acceptable for you to
routinely report your symptoms online? (daily, weekly,
monthly)
 Do you envisage any practical problems using a system like
this?
 If you were asked to do this, would you assume that this
information is being shared with your clinical team?
 Would you be happy for this information to be shared with
your clinical team?
 Can you think of any other advantages/benefits of using a
system like this?
 Can you think of any other disadvantages of using a system
like this?
 Anything else?
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research nurses, hospital-based trials assistants and
data managers, and trial unit staff. Staff were initially
approached about the interview via email. The staff
sampling aimed for a mixture of staff roles and number
of years working in early phase trials.
Procedure
Following ethical approval from National Health
Service Research Ethics Committee (ref:16/NW/0659)
and individual hospital approval, recruitment took
place at two hospitals and a university-based clinical
trial unit from December 2016 to November 2017. All
participants received a written study information sheet
and gave informed consent in writing or verbally
(recorded). Interviews took place at a time and place
preferred by the participant (hospital, telephone, or
patient’s home), and some patient interviews took place
alongside a family member. Interviews lasted between
12 and 70 min (average 32 min), were audio-recorded,
then downloaded onto secure-access university server,
transcribed, and anonymised. Transcripts were not
reviewed by any participants as it was considered inap-
propriate to re-contact patients who were near the end
of treatment options and staff who had clinical priori-
ties. Data collection continued until data saturation
was reached (i.e. no new issues emerging).
Data analysis
Transcripts were coded independently by two research-
ers (F.K. and L.S.) using the framework approach.38
Framework analysis uses a systematic process of sifting,
charting, and sorting the data into key themes using five
stages: familiarisation, developing a thematic frame-
work, indexing, charting and mapping, and interpreta-
tion. This method is suited to research that has specific
questions, limited timescale, and an a priori set of
issues.39 The thematic framework was based on the a
priori interview schedule (Table 1), but additional emer-
gent themes were identified. Data analysis took place
between February and June 2019 and was initially com-
pleted separately (patient/staff) using the data analysis
software NVIVO (https://www.qsrinternational.com/
nvivo). Cross-cutting analysis then identified three key
themes. Data analysis meetings were held throughout
to ensure consistency of coding/interpretation.
Results
Thirty-two interviews (patients – 11 telephone and 5 in
person; staff – 9 telephone, 7 in person) were con-
ducted. Due to limited resources, the number and rea-
sons for participant decliners were not recorded.
Table 2 illustrates the sample characteristics. The
patients were aged 43—80 years (median 64 years), had
various cancer diagnoses, and were split across phase I
and II trials (N = 9/N = 7). Staff participants included
consultants (N = 5), research nurses (N = 4), hospital-
based trial staff (N = 5), and trial unit staff (N = 2)
including a trial manager and statistician, and most had
worked in this area for 5+ years (N = 14).
Findings are presented under three key themes that
reflect the theoretical framework depicted in Figure 1.
Example excerpts for each theme are provided in the
supplementary tables (see Appendix 1 of Supplemental
Material) and in Table 3.
Theme 1: patient experiences
This theme reflects the views of both patients and staff
on the patient experiences on early phase trials. These
Table 2. Details of participant samples.
Patient sample N (%)
Age
Median 64 years
Range (years) 43–80 years
40–49 4 (25%)
50–59 2 (12.5%)
60–69 6 (50%)
0–79 3 (18.75%)
80+ 1 (6.25%)
Gender N (%)
Male 7 (43.75%)
Female 9 (56.25%)
Phase I or phase II
Phase I 9 (56.25%)
Phase II 7 (43.75%)
Cancer site
Bladder 2 (12.5%)
Brain (glioma) 1 (6.25%)
Breast 1 (6.25%)
Colorectal 4 (25%)
Head and neck 3 (18.75%)
Melanoma 2 (12.5%)
Mesothelioma 1 (6.25%)
Myeloma 2 (12.5%)
Staff sample
Professional role
Consultant 5 (31.25%)
Research nurse 4 (25%)
Hospital-based clinical trial
assistant/data manager
5 (31.25%)
Trial unit staff 2 (12.5%)
Length of time working in
early phase trials (years)
1–2 1 (6.25%)
3 2 (12.5%)
5 2 (12.5%)
6 2 (12.5%)
7+ 9 (56.25%)
Involvement in phase I or phase II
Both 13 (81.25%)
Phase I only 1 (6.25%)
Phase II only 2 (12.5%)
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Table 3. Theme 3: views on ePRO-AE.
Subthemes Example excerpts
1. Patient views 1. ‘Yes I think it would be a good idea, I tend to write them in my diary.if you don’t write them
down you tend to forget because it’s 3 weeks between seeing the doctor’ (Patient 12)
2. Frequency 2. ‘.If you have an open login system like that where you can just go in if you need to you could up
it, couldn’t you? You could, you know, maybe once a week as a regular thing for me but if I could
come in because it’s Tuesday and I’m suddenly like this I might have something I want to put in the
system. If we had that flexibility as well, I don’t know’. (Patient 3)
3. ‘I suppose it does depend on the nature of the study and sort of what you might be expecting, but
it’s also a balance and not wanting to make it too burdensome that it’s too frequent. So I would
have thought that weekly would be sort of reasonable’. (Consultant 3)
3. System functionality See Table 4
4. Benefits 4. ‘a patient who can report their symptoms once and twice a week may not be seen in clinic for
2 weeks. So how they felt the last week when they felt dreadful to how they feel this week, you
can’t always express your symptoms the same. You know, so they might have already forgot how
sick they felt and how tired they were, but at that point it were really severe. So I think it will be a
really successful system to be honest’. (Clinical trial assistant 1)
5. ‘it’s more convenient for the patient, that you don’t have to try and get on the phone to somebody
and get through the switchboard to the departmental secretary, to the nurse, and wait for
someone to call you back. If there’s no problem you can go ahead and it’s gone in, and if there is a
problem you’ve put all the info in front of, hopefully, whoever is going to come and respond’.
(Patient 5)
6. ‘So it might speed up the reporting to us. It probably going to be quite a comprehensive list of
things because the patients then going to think ‘‘oh I’ve got this I’ve got that’’. Whereas our
information currently comes from the medical records where the doctor then writes down a list
of things ‘‘Mrs Smith had such and such’’ and he might miss 2 or 3 things off. So I think it would
probably improve what we’re getting’ (Trial unit staff 2)
7. ‘we’re probably fairly good at picking up on the serious toxicities because we encourage patients to
contact us, try to get them to contact us early.we may well miss sort of routinely capturing is the
breadth of grade 1 and grade 2 toxicities, which actually I think sometimes patients either forget to
mention or perhaps think themselves that they’re not important enough to mention.perhaps
capturing the breadth of lower grade toxicities could be useful and certainly have an impact on the
quality of life of the patient and their overall experience with the treatment’. (Consultant 4)
8. ‘It feels a bit like a safety net. Although there’s nobody there to talk to at the time and they’re little
things that you wouldn’t ring up about, it just feels you’ve put it down in writing and somebody
somewhere is going to read it’. (Patient 8)
5. Challenges 9. ‘the advantage if you like with e-reporting is that patients can do it at 10 o’clock at night or 2 in the
morning, it’s a real-time capture. But there’s not necessarily going to be somebody real-time to
review that. I don’t think that there’s the man power’ (Consultant 4)
10. ‘who’s going to police it, who’s going to do something about the adverse events, how quickly will it
be acted on, who’s responsibility is it to look at it. It’s going to need to be accessed several times a
day or ping into somebodies inbox who will action it if necessary that day because patients will
assume that as they’ve reported it that that’s all they need to do’. (Consultant 2)
11. ‘I would only want to know I think grade 3 and above. So something that would, although with
somethings it might be quite good to know about grade 2 you know because they’re brewing.
Maybe grade 2 and above, yeah’ (Consultant 2)
12. ‘I think that it could be that it’s something that’s difficult for patients to grade their own experience
perhaps. And inevitably they’re going to be grading it...compared to experiences perhaps of
treatment that they’ve had before. You know, previous chemotherapy or whatever, and may use
that as a benchmark. So there’s certainly, likely to be subjective interpretation of the results
depending on, you know from patient to patient. And I think that the other main weakness is going
to be for the patient to be able to differentiate between a treatment related side effect or
symptom, compared to disease related.I think that can be quite difficult’. (Consultant 4)
13. ‘the pharma companies see everything that goes into the case notes or everything on the
electronic patient record as source data. So then, I don’t know whether any of this will actually go
into the patient’s record.But as soon as it does that in a trial the company will then say ‘‘well
actually on ePRIME the patient said this but you only said it was a grade 1 diarrhoea. ’’ and
generate lots and lots of pharmacovigilance queries. Not saying that’s the wrong thing to do I
suppose it’s that, as they interpret the regulatory framework as being you can’t go wrong with
more and more information, it has its knock on consequences of somebody has to then go on and
screen that and vet that. How does it marry up with what the doctors written and where’s that
kind of certainty so it’s, that could be an issue’. (Consultant 1)
14. ‘If we got that big long list and therefore what do we do with it, do we assume that everything the
patient’s reported needs to be reported in our trial? Whereas I think ours gets like you said a
doctor filter on it and then its reported what we want.we don’t necessarily want everything that
the patient happens to mention that week’. (Trial unit staff 2)
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trials provided patients with a last option for treatment
and were described as intense with very frequent hospi-
tal visits. Clinical staff spoke about how patients were
often a self-selected group: fit enough for treatment,
despite being in the terminal stages of their cancer. The
following patient experience subthemes explore: infor-
mation provision, contact and monitoring symptoms,
and symptom/side effect experiences and reporting (see
quotes 1–10 – Table 5 in Appendix 1 of Supplemental
Material).
Subtheme 1: information provision. Most patients and clini-
cal staff were positive about the detailed information
they received or gave to patients joining a trial. Specific
information sheets described the study process and pos-
sible side effects, but clinical staff emphasised how they
verbally discussed the inherent uncertainty owing to
this being a new drug/trial. They also emphasised how
new safety information may emerge, resulting in addi-
tional tests or processes. The trial unit staff emphasised
the long list of potential symptoms given to patients,
often split into common/expected side effects versus
infrequent/serious symptoms (quote 1 – Table 5 in
Appendix 1 of Supplemental Material). Some patients
discussed the key symptoms they were aware of, while
others described less specific information and were
unclear on the symptoms they should report. Patients
varied in whether they thought the information level
was sufficient and reasonable or overwhelming (some-
times the case for older patients), and some candidly
admitted they didn’t always read everything in detail
(quotes 2/3).
Subtheme 2: contact and monitoring symptoms. The fre-
quency and content of contact were largely protocol
driven. Staff described an ‘intensive’ process and all
participants highlighted regular (weekly, sometimes
daily) appointments, especially in phase I trials, but
how these might reduce as treatment is established.
Patients were accepting of the intensive schedules and
felt well looked after. The research nurse was usually
the patients’ primary contact, and most were clear on
the process/contact numbers to report symptoms dur-
ing office hours and out-of-hours. However, confidence
in out-of-hours service was related to whether they had
used it (quotes 4/5). Patients were encouraged to phone
between appointments with new symptoms, and staff
sometimes made unprompted phone calls to check on
patients. In the detailed clinic review appointments
(quote 6), clinical staff discussed how they aimed to
record what symptoms patients experienced compre-
hensively and accurately as per trial sponsor require-
ments (quote 7).
Subtheme 3: symptoms/side effect experiences and
reporting. The patients interviewed had experienced a
range of symptoms, such as rashes, lethargy, nausea,
and stomach upsets, but few had required admission.
Both clinical staff and patients (but not trial unit staff)
highlighted that under-reporting symptoms was
Theme 1: 
Paent 
experiences
1.Informaon 
provision
Theme 3: 
Views on ePRO-
AE reporng
2.Contact & Monitoring 
symptoms 3.Symptoms/side effect 
experiences & reporng
1.Current 
data flow
2.ePRO-AE 
data flow
1. Paent views 2.Frequency
3.System 
funconality
4.Benefits
5.Challenges
Current pracce Future of ePRO reporng
Theme 2:
Trial data 
flow
Figure 1. Themes and subthemes of the data analysis.
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common, especially low-severity symptoms. Patients
did not always report symptoms immediately but
instead waited for routine appointments (quotes 8/9).
Clinical staff suggested that under-reporting was due to
patients forgetting, not perceiving mild symptoms to be
important, being an ‘expected’ side effect or concern
their treatment would be stopped. Clinical staff dis-
cussed the diversity of patient recording/reporting and
how real-time self-reporting may encourage more accu-
racy (quote 10).
Theme 2: trial data flow
This theme reflects the flow of data in trials, both in
terms of current practice and views about the future of
ePRO-AE.
Subtheme 1: current data flow. The current well-
established practice was reported (illustrated in Figure
2 – ‘Traditional approach’), consisting of collecting
adverse events in trials through clinic visits and phone
calls, recording them using CTCAE criteria by
hospital-based staff who then upload to the trial spon-
sor while trying to determine causality (quote 1 – Table
6 in Appendix 1 of Supplemental Material).
Trial unit staff highlighted differences between trial
types: phase I symptoms are collected as soon as possi-
ble in free-text format, but for phase II expected symp-
toms are explored per treatment cycle (quote 2). The
high volume and complexity of information, along with
the requirement to attribute causality and the clinical
relevance of symptoms were described as particularly
Paent has 
symptom 
at home
A B C D
KEY:
AE = adverse event
IMP = invesgaonal medicinal product
eCRF = electronic clinical research form 
ePRO = electronic paent reported 
outcome 
SAE = serious adverse event 
PI = principal invesgator
Tradional adverse event 
reporng approach in trials:
ePRO adverse event reporng approach in trials and reconciliaon opons:
Paent completes online system (may ring research nurse/emergency number too)
Local PI receives 
ePRO directly (trial 
office does not 
receive)
Trial office & local PI 
receive ePRO data
Trial office receive 
ePRO
Trial office receive 
ePRO
• Local study PI uses 
ePRO informaon 
clinically & 
indicates if related 
to IMP (causality)
• Upload to eCRF
• Local study PI uses 
ePRO informaon 
clinically & 
indicates if related 
to IMP (causality)
• Upload to eCRF
Reconciled report Reconciled report
• Local study PI 
completes own 
assessment 
(no access to 
ePRO) & indicates 
if related to IMP 
(causality)
• Upload to eCRF
• Local study PI 
completes own 
assessment 
(no access to ePRO) 
& indicates if 
related to IMP 
(causality)
• Upload to eCRF
Non-reconciled, keep 
separate reports
Does data match?  
Reconciled report at 
analysis using both data
Paent rings research 
nurse/emergency 
number or waits for 
next appointment
Research nurse 
records AE
• Study PI indicates if 
related to IMP 
(causality)
• Hospital-based trial 
team upload to eCRF
(within 24 hours if SAE)
Trial office receive 
clinician-recorded AE
Clinical use of AE data:
AE interpreted by 
clinicians. Under-reporng 
possible & may miss some 
AEs not reported by 
paents
Clinical use of AE data:
Communicate ePRO-AE to 
local PI in real-me to 
inform their AE grading
Use ePRO-AE in real-me 
unfiltered to direct clinical 
decisions
Collect ePROs & review at the end of trial 
without clinical review
Trial office receive 
clinician-assessed AE 
informed by ePRO-AE
Trial office receive 
clinician-assessed AE 
informed by ePRO-AE
Trial office receive 
clinician-assessed AE 
& during analysis 
explore differences
Trial office receive 
clinician-assessed AE
Figure 2. Traditional and ePRO-AE approaches. Reconciliation options informed by Di Maio et al. (2016): (a) Local PI/clinician
receives ePRO direct (trial office does not receive) and uses data in their own assessment, (b) ePRO data go to both trial office and
local PI to use in own assessments; (c) patient and clinician data collected separately (i.e. PI does not have access to ePRO) and only
reconciled at data analysis stage (e.g. queries about discrepancies across paired data and select data that show most severe toxicities
at any given time), (d) patient and clinician data collected and reported completely separately without any reconciliation.
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challenging (quote 3). Trial unit staff also highlighted
how they rarely received any patient-reported data
directly in early phase trials, instead all data is generally
received from hospital-based teams, the only exception
being a trial where patient-reported questionnaire data
were received as part of the protocol outcome mea-
sures, but only explored during the final data analysis
rather than in real-time (quote 4).
Subtheme 2: ePRO-AE data flow. Varying opinions were
voiced about the potential ePRO-AE data flow (data
going to clinical team versus trial office). Many patients
assumed their clinical team would receive it and were
happy with this, emphasising how they felt it needed to
be acted on as part of routine clinical management
(quote 5). Clinicians were positive about being able to
cross-check the patient-reported data with their assess-
ments, enabling a thorough monitoring of patients’
wellbeing (quote 6). However, some clinicians raised
concerns about the volume of data requiring clinical
review and uploading to trial sponsors, and some felt
the data should go directly to the trial sponsor. In con-
trast, trial unit staff were resolute that ePRO-AE data
should not be received by the trial office without first
being reviewed by clinicians (quote 7). They viewed the
online system as a tool to help clinicians establish toxi-
cities, rather than allowing the data to directly feed into
the trial outcomes.
Theme 3: views on ePRO-AE
This theme explores participants’ views on ePRO-AE
in terms of general perceptions, frequency of reporting,
system functionality, benefits, and challenges. Table 3
provides example excerpt quotes illustrating the data.
Subtheme 1: patient views. Overall, within the patient
sample, 11/16 were positive about ePRO-AE (quote 1)
highlighting that it is an instant record. Two patients
discussed only being able to record when feeling well
and three did not have the Internet or had too few
symptoms.
Subtheme 2: frequency. Views varied on the desired fre-
quency for completing ePRO-AE. ‘Weekly’ was the
optimal frequency among seven patients and four staff
(quotes 2/3), but several also wanted flexibility to sub-
mit ad hoc reports for any new symptoms, and three
other patients wanted a purely ad hoc system. Four
clinical staff and a patient suggested twice weekly or
daily completions, whereas five staff (both trial unit
staff, two trials assistants, and a consultant) and two
older patients felt monthly was sufficient.
Subtheme 3: system functionality. Participants made
various suggestions about the functionality of any
ePRO-AE system (Table 4). These included receiving
reminders, question formatting, adding other or unan-
ticipated symptoms, longitudinal graphs for clinicians,
and patient prompts to contact their trial team.
Subtheme 4: benefits. Most participants recognised the
value of capturing more symptom information. Some
felt that 24/7 access was particularly beneficial, and
most emphasised an online system could result in less
forgetting and more accuracy on symptom progression
or severity in real-time (quote 4, Table 3). Participants
felt that this would supplement the regular trial-related
visits, guiding symptom discussions (quote 5), and some
clinical staff emphasised that this could save time and
reduce workload if they had access to reports before
routine visits. Trial unit staff emphasised that it pro-
vided a more consistent and comprehensive hospital-
based adverse event assessment, providing clinicians
with more information to assess and if relevant pass
onto the trial unit (quote 6).
Table 4. Theme 3: Subtheme 3: system functionality suggestions by patients and staff.
Patients Staff
Reminders
Question format – checklist+open question for other
symptoms/issues
User-friendly and functional
Quick report function (e.g. to report no symptoms
or review last submission – verify still same)
Follow-up if serious or advice online
Acknowledgement report received
Staff functionality
Batching emails/alerts (not multiple emails)
Flexibility to tailor to trial
Function to see trends overtime (e.g. longitudinal graphs)
Patient functionality
Ad hoc access
Function to add ‘other’ or unanticipated symptoms
Advice to contact trial team/not substitute for phoning for advice
if unwell/onus on patient to contact hospital
User-friendly for patients and staff (e.g. visually inclusive – large buttons)
Language simple/patient-friendly
Security
Access from mobiles
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Some clinicians felt that the system would more fre-
quently capture low-grade toxicity, which may improve
outcomes if mild symptoms are identified and managed
earlier (quote 7). This mirrored patients’ views on how
they did not always report mild symptoms but they val-
ued being able to record them on the online system
(quote 8).
Subtheme 5: challenges. Some patients and staff men-
tioned IT security issues such as data confidentiality,
and the importance of a user-friendly system. Access to
the Internet and computer skills were also raised.
Patient burden was highlighted by several staff,
although most patients indicated their willingness to
take part in ePRO-AE alongside routine trial-related
visits.
Clinical staff worried predominantly about patient
safety, this being their primary responsibility (quotes 9/
10), which was linked to the need to monitor ePRO-AE
data. Some staff emphasised patients should continue
using the current emergency/out-of-hours telephone
numbers to report serious symptoms, rather than use
an ePRO-AE system as they were unsure they could
monitor and respond in real-time, especially with the
complexity of out-of-hours staffing. However, other
consultants and research nurses were keen to be alerted
to severe or high-grade symptoms (grade 2+ /grade
3+ ; quote 11) or symptoms that had changed using
trial-specific algorithms. Clear staff responsibilities and
a robust mechanism for receiving alerts (if used) or
reviewing data were considered fundamental to ensure
that serious symptoms were not missed.
One patient, two consultants, a clinical trial assis-
tant, and both trial unit staff members highlighted the
difficulty of attributing symptoms to trial drugs. Some
felt that ePRO-AE could increase the ‘noise’ of patients
reporting cancer-related symptoms, late effects from
previous treatments, or other comorbidities (quote 12).
This links to two other issues – first the potential
increased workload from ePRO-AEs requiring review
(quote 13) and data flow in terms of who receives the
data with what responsibility (quote 14 and relates to
Theme 2).
Discussion
This study explored the experiences and views of oncol-
ogy patients, clinical, and trial-specific staff on using
ePRO-AE in early phase trials. The patients disclosed
under-reporting of mild symptoms and suggestions that
an ePRO-AE system may gather more accurate data
about the breadth of toxicities experienced. Although a
patient-reported symptom may not be due to the trial
drug, which could be viewed as a pitfall of an ePRO-
AE system, this work highlights that the current prac-
tice and possible under-reporting does not allow all
potential associations to be explored. Overall, most
interviewees who had experience of early phase trials as
a patient or clinician viewed positive benefits and
added value of an ePRO-AE system and offered useful
suggestions on potential challenges and implementation
issues.
Clearly our results showing under-reporting of
milder symptoms is significant. From a trial-related
perspective, this means the adverse event profile of new
drugs is likely to miss some low-grade toxicities which
could have a significant impact on patient’s quality of
life and adherence to treatment.40 Furthermore, clinical
care may be suboptimal if appropriate advice and/or
supportive treatments are not being provided.
Importantly, we are not aware of other studies high-
lighting under-reporting from the perspective of
patients. Previous research has emphasised under-
reporting among clinicians scoring adverse events,2,7,41
but our study suggests that filtering occurs in what
patients tell their clinicians, even in the early phase trial
setting.
To date, patient self-reporting of adverse events in
early phase trials has been explored in a handful of
studies, where patients completed adverse event moni-
toring on paper32,33 or tablet computers in the hospi-
tal.15,34,35 Our study highlights that most patients are
willing to regularly and remotely access an online sys-
tem in addition to their trial-related appointments.
However, a feasibility study is now required to explore
the real-time challenges/logistics, including patient bur-
den, which may become visible once the ePRO-AE sys-
tem is implemented in clinical practice.
In our study, concerns about patient safety, work-
load for clinical and trial staff, and data flow and moni-
toring of ePRO-AEs were raised by most clinical,
hospital-based trial staff, and trial unit staff. Safety
concerns focused on ensuring that no important symp-
toms are missed – either by restricting the system to
non-severe symptoms or ensuring a robust mechanism
for prompt clinical review of all patient-reported data.
The latter could be greatly facilitated by real-time alerts
based on pre-defined algorithms to multiple stake-
holders. Workload concerns were raised by some clini-
cal staff, but others felt having access to ePRO-AE data
could improve their efficiency by promptly identifying
and addressing ePRO-AE reported issues rather than
having to collect additional data themselves. Clearly
these practical implications for staff require careful
exploration within any feasibility study, and they would
depend on how any ePRO-AE data were used both
clinically and in the trial outcomes. In the literature,
various options for the reconciliation of clinician versus
patient reports in trials have been suggested2 (see
Figure 2 for ePRO approach). Clinically, the data could
be shared with clinicians (options (a)/(b) in Figure 2) or
not shared (options (c)/(d)), and clinicians could spend
time filtering the ePRO-AE data or use unfiltered to
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inform clinical decisions directly. These options have
differing responsibilities and workload implications for
clinicians or trial-related staff and would need thorough
consideration and testing in any future use of a trial
ePRO-AE system.
Regardless of where the online self-reported infor-
mation is transferred, it is important to inform patients
where their data go, and if and when it will reviewed by
their clinical team. This relates to Kim et al.14 who
highlighted that patient-reported outcome data without
clinical interpretation is not considered safety data and
how clinical assessment is still needed to assess CTCAE
grade and attribution. This is in line with the trial unit
staff interviewed who felt clinicians should review any
ePRO-AE data, rather than assuming that all patient-
reported data are relevant to the trial outcomes.
However, Basch argued that patient-reported data are
different from clinician-reported data, they are comple-
mentary, and it is relevant to collect both to compre-
hensively capture the toxic impact of treatments.8,19
This study was conducted in the North of England,
across two centres, which is a limitation. The sample
was small, which means we cannot generalise the views
expressed. However, the views around using ePRO-AE
are likely to be of interest to other stakeholders work-
ing on trials nationally and internationally.
Focusing on patients currently or recently enrolled
on an early phase trial at two hospitals also influenced
the populations available for sampling in terms of ages,
malignancies and treatments. Future similar studies,
perhaps employing mixed methodology, could explore
experiences and expectations of ePRO-AE systems
across other sociodemographic and clinical groups. We
note that patients recruited were all aged above
40 years. Exploring the views of ePRO-AEs in adoles-
cent and younger adult patients would provide addi-
tional insights given their increased familiarity with
technology and this may help improve clinical trial
acceptability in this population.42 Furthermore, asking
patients if they had any experience of self-reporting
(paper or electronically) adverse events or other PROs
in their trials would have been useful as patient’s previ-
ous experiences may have influenced their viewpoint on
the proposed ePRO-AE.
Finally, we did not interview any pharmaceutical
personnel or representatives of regulatory agencies, and
the findings may have benefitted from that additional
viewpoint. Further investigation is still required on
whether ePRO-AE collection would be acceptable from
an early phase regulatory perspective. However, ePRO
methods will inevitably continue to grow in our increas-
ingly technologized society, so it is important that more
work is undertaken in this area.
Following this study, we are conducting a small fea-
sibility pilot of an ePRO system among oncology
patients registered on active phase I/II trials. The pilot
is recruiting patients within 1 month of starting
treatment and includes automated weekly reminders
but the system is open should participants wish to
report more frequently. The ePRO data are being sent
directly to the trial office, but the research team is
alerted to any severe symptoms (grade 3+ ). This
allows the research team to inform the patient’s clinical
team (requested by the trial teams) and explore the vol-
ume of alerts this generates to inform the future design
of the ePRO system.
Conclusion
Patient-reported outcome adverse events reporting is
increasingly regarded as valuable and complementary
to the long-standing clinician-reported toxicity process
within clinical trials. The patient voice should be pres-
ent in order to improve the capture of drug-related
symptoms and side effects.8 With the capability to col-
lect ePRO-AEs directly from patients and transfer in
real-time to the sponsor or patient’s clinicians, it is
timely to consider the benefits and challenges of this
and how it can be practically implemented to enhance
trial outcomes. In addition, lessons have been learned
during the COVID-19 pandemic for using remote
methods (including ePRO-AEs) to monitor some trial
patients (e.g. 12+ weeks on trial, no safety concerns).30
Further national collaboration between clinicians, trial
sponsors, and researchers is required to inform the
future debate on this important area.
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